US Patent Issued to Kuleon on July 1 for "Mixed serotonin 5-HT2A/2C receptor agonists and methods for treating pain and depression" (Washington Inventor)

ALEXANDRIA, Va., July 3 -- United States Patent no. 12,344,582, issued on July 1, was assigned to Kuleon LLC (Seattle).

"Mixed serotonin 5-HT2A/2C receptor agonists and methods for treating pain and depression" was invented by David Gilles (Seattle).

According to the abstract* released by the U.S. Patent & Trademark Office: "Hallucinogenic and non-hallucinogenic serotonin receptor agonists are disclosed herein in addition to methods of making and using the same."

The patent was filed on Dec. 4, 2024, under Application No. 18/968,441.

*For further information, including images, charts and tables, please visit: http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND...